Go

Breaking News on Cosmetics Formulation & Packaging - Europe US edition

All feeds

News headlines > Formulation & Science

Text size Print Email this page

ISCC science meeting showcases industry breakthrough

By Katie Bird, 06-Dec-2007

Related topics: Colour Cosmetics, Hair Care, Packaging, Skin Care

Botaneco, a subsidiary of Canadian based biotech firm SemBiosys, is to present its lipid harnessing technology at the meeting for the International Society of Cosmetic Chemists (ISCC) in New York.

The society hopes to foster the advancement of cosmetic science through public meetings and disseminations and is one of the 45 member organisations within the International Federation of Societies of Cosmetic Chemists (IFSCC).

Botaneco, a recently formed subsidiary of SemBioSys, will detail their work on harnessing oilseed oleosomes at the society's annual meeting that kicked off today and continues tomorrow in New York.

The technology can provide natural alternatives to synthetic emulsions in the manufacturing of sunscreens, lotions and other personal care products, according to the company.

The first of Botaneco's products to be created using the technology safflower oleosomes called Hydresia, was recently launched during the Cosmetic Chemists show in California.

The product is extracted from oil seed, its oil-in-water emulsion naturally contains moisturizing oils along with emulsifying proteins and phospholipids, and the technology behind it is described by the company as a 'technological and performance breakthrough'.

Botaneco highlight that the technology and resulting products are environmentally friendly as little energy is needed during the extraction and production process.

"The performance of Hydresia is equal to or better than its synthetic counterparts and the ability to cold process formulation with Hydresia reduces energy and labour costs," said Botaneco's Andrew Baum.

The business unit was formed in August of this year and it is expected to serve as SemBioSys' 'cash cow', allowing the parent company to continue its pharmaceutical research, which is not profitable in the short-term.

"The Boteneco business unit gives SemBiosys increased control over its commercial activities targeting the multi-billion dollar personal care and dermatology marketplace, and offers Sembiosys a focused organization with all the resources to make this launch successful for our stakeholders," said Baum.